No registrations found.
ID
Source
Brief title
Health condition
Sentinel Lymph Node Biopsy in breast cancer and melanoma patients. Outcomes are potentially of benefit for more solid cancer patients.
Sponsors and support
Intervention
Outcome measures
Primary outcome
1. The proportion of sentinel nodes correctly detected with the magnetic technique (magnetometer) as compared to the combined technique (visually and/or using the gammaprobe).
2. The proportion of patients in which the sentinel lymph nodes could successfully be detected (detection rate) using the magnetometer.
3. The number and percentage of sentinel lymph nodes correctly diagnosed to be metastatic using ex vivo MRI.
4. The number and percentage of sentinel lymph nodes correctly diagnosed to be non-metastatic using ex vivo MRI.
Secondary outcome
5. The iron content in the dissected lymph nodes (average, minimum and maximum) in relation to the image quality;
6. The image parameters indicative for the presence of lymph node metastases;
7. The requirements in detection depth and minimally detectable mg iron per node for future magnetometers.
Study objective
The sentinel lymph nodes (SLN) are the first lymph nodes to drain the tumor site and therefore the first lymph nodes to bare metastases. Hence the importance to investigate these lymph nodes to define the best treatment strategy. Currently, in a.o. breast cancer and melanoma patients, the sentinel lymph nodes are intraoperatively detected, both visually and by using a gamma probe, following the subsequent injections of radioactive tracer (Tc 99-m nanocolloid) and blue dye (Patent Blue). Histopathological investigation of the resected sentinel lymph nodes should then confirm the presence or absence of metastases. The conventional methods for sentinel lymph node biopsy suffer from disadvantages, such as the use of radioactive materials and the fact that node-positive patients require multiple surgical procedures. At the NeuroImaging (NIM) group of the University of Twente, we investigate a magnetic, radiation-free, procedure for sentinel lymph node detection and evaluation. Several aspects of this procedure have been investigated in separate studies. Results were promising, showing a detection rate of the sentinel node non-inferior to the detection rate with the existing technique and proving the feasibility to visualize the sentinel nodes in preoperative MRI. However, the doses and volume of the injected magnetic tracer (SuperParamagnetic Iron Oxide particles, SPIO), was relatively high. The high dose of iron potentially leads to difficulties in evaluating lymph nodes with small metastases and to substantial skin staining. Additionally, the high volume of injected tracer might in some cases lead to a non-physiological uptake of iron in the lymph vessels, reducing the reliability for detecting (solely) sentinel lymph nodes. In this study, the aim is to investigate the feasibility of using low dose SPIO (50x lower than the previously safely used dose) for both preoperative evaluation and intraoperative detection of the sentinel lymph node in breast cancer patients.
Study design
Interim analysis and evaluation of the protocol after:
every 10 performed procedures
every 5 completed procedures on patients with macrometasastes
every 5 completed procedures on patients without metastases
Intervention
Two peritumoral injection of SPIO (SIENNA+), 1 mg in 1 mL following the injection of TC99m and lymphoscintigraphy.
The intraoperative detection of the SPIO accumulation in SLNS by a handheld magnetometer in addition to the conventional detection of accumulated TC99-m nanocolloid by the gammaprobe.
The imaging part of this study is performed ex vivo and post-surgery.
University of Twente<br>
P.O. Box 217
M. Heijblom
Enschede 7500 AE
The Netherlands
+31 (0)53 4893877
m.heijblom@utwente.nl
University of Twente<br>
P.O. Box 217
M. Heijblom
Enschede 7500 AE
The Netherlands
+31 (0)53 4893877
m.heijblom@utwente.nl
Inclusion criteria
Adult, clinically (palpation and ultrasound) node negative, patients that are diagnosed with invasive breast cancer or high grade ductal carcinoma in situ and that are scheduled for a two-day SLNB procedure and that gave informed consent for participation to the study;
Exclusion criteria
1.Patients incapable of giving informed consent for participation to the study;
2.Intolerance / hypersensitivity to iron or dextran compounds;
3.Patients that have received neoadjuvant chemotherapy in the period of 5 years prior to this study.
4.Pregnant or lactating patients
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4713 |
| NTR-old | NTR4858 |
| Other | NL49285.044.14 : METC TWENTE P14-32 |